| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 20% | $66,072,258 | 7,135,233 | Third Rock Ventures V, L.P. | 31 Dec 2024 | |||
| Cormorant Asset Management, LP | 6.7% | $94,817,874 | 3,192,521 | Cormorant Asset Management, LP | 30 Sep 2025 | |||
| Sofinnova Venture Partners XI, L.P. | 4.2% | $29,155,258 | 1,947,579 | Dr. James I. Healy ("Healy") | 11 Sep 2025 | |||
| JOHNSON & JOHNSON | 4.9% | $53,000,690 | 1,784,517 | JOHNSON & JOHNSON | 30 Sep 2025 |
As of 30 Sep 2025, 123 institutional investors reported holding 49,276,697 shares of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP). This represents 103% of the company’s total 47,649,567 outstanding shares.
The largest institutional shareholders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) together control 95% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TRV GP V, LLC | 15% | 7,135,233 | 0% | 60% | $211,916,420 |
| FMR LLC | 15% | 6,916,995 | +26% | 0.01% | $205,434,751 |
| ARCH Venture Management, LLC | 7.8% | 3,728,738 | 0% | 22% | $110,743,519 |
| Capital International Investors | 7.1% | 3,402,529 | +31% | 0.02% | $101,055,111 |
| Cormorant Asset Management, LP | 6.7% | 3,192,521 | +8.6% | 6.5% | $94,817,874 |
| GOLDMAN SACHS GROUP INC | 5.1% | 2,421,976 | +96% | 0.01% | $71,932,687 |
| Sofinnova Investments, Inc. | 4.1% | 1,947,579 | -2.4% | 3.5% | $57,843,096 |
| JOHNSON & JOHNSON | 3.7% | 1,784,517 | -29% | 11% | $53,000,155 |
| VANGUARD GROUP INC | 3.4% | 1,626,538 | +47% | 0% | $48,308,179 |
| BlackRock, Inc. | 3.3% | 1,568,081 | +29% | 0% | $46,572,006 |
| BAKER BROS. ADVISORS LP | 3.2% | 1,547,090 | +181% | 0.33% | $45,948,573 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.3% | 1,102,391 | -28% | 0% | $32,742,000 |
| Siren, L.L.C. | 2.2% | 1,053,469 | +178% | 1.2% | $31,288,029 |
| TRV GP VI, LLC | 2% | 969,218 | 0% | 26% | $28,785,775 |
| Vestal Point Capital, LP | 2% | 950,000 | 1.3% | $28,215,000 | |
| Polar Capital Holdings Plc | 2% | 938,952 | 0.13% | $27,886,874 | |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 1.9% | 892,258 | +266% | 0.01% | $26,500,063 |
| ALLIANCEBERNSTEIN L.P. | 1.8% | 855,620 | -26% | 0.01% | $25,411,914 |
| T. Rowe Price Investment Management, Inc. | 1.5% | 707,508 | +15% | 0.01% | $21,013,000 |
| UBS Group AG | 1.2% | 558,073 | +104% | 0% | $16,574,769 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 533,403 | +60% | 0% | $15,846,082 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.94% | 450,000 | 0.02% | $13,365,000 | |
| PERCEPTIVE ADVISORS LLC | 0.85% | 403,923 | 0.35% | $11,996,513 | |
| STATE STREET CORP | 0.78% | 371,626 | +24% | 0% | $11,037,292 |
| MORGAN STANLEY | 0.58% | 274,568 | +295% | 0% | $8,154,670 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 10,220 | $309,596 | +$107,751 | $30.34 | 4 |
| 2025 Q3 | 49,276,697 | $1,463,478,389 | +$335,895,378 | $29.70 | 123 |
| 2025 Q2 | 38,494,803 | $437,875,302 | +$4,896,109 | $11.37 | 81 |
| 2025 Q1 | 38,102,588 | $382,320,486 | +$11,241,439 | $10.03 | 77 |
| 2024 Q4 | 36,577,539 | $648,890,746 | +$1,212,039 | $17.74 | 69 |
| 2024 Q3 | 28,374,042 | $580,443,876 | +$35,923,807 | $20.48 | 54 |
| 2024 Q2 | 25,558,517 | $593,435,106 | +$593,435,113 | $23.26 | 35 |